{"entity":{"id":"tng462","kind":"drug","name":"TNG462","aka":[],"tldr":"TNG462 is an experimental small-molecule drug from Tango Therapeutics in phase 2 trials for pancreatic ductal adenocarcinoma and non-small-cell lung cancer, aimed at PRMT5 (MTAP-deleted cancers).","summary":"TNG462 is a small-molecule drug developed by Tango Therapeutics and Servier Bio-Innovation. Its target is PRMT5 (MTAP-deleted cancers) (the sponsor names PRMT5). The sponsor states: A selective PRMT5 inhibitor administered orally, developed for tumours with an MTAP homozygous deletion. ClinicalTrials.gov describes the intervention as: TNG462, a selective PRMT5 inhibitor, will be administered orally. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in pancreatic ductal adenocarcinoma and non-small-cell lung cancer. The largest, NCT05732831, plans to enrol 225 participants with primary completion expected 2027-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of TNG462","url":"https://clinicaltrials.gov/search?intr=TNG462"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","nsclc"],"sections":[],"technologies":[],"targets":["prmt5-mtap"],"drugs":[],"companies":["tango-therapeutics","servier"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06922591","nct06188702","nct05732831"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule","mechanism":"A selective PRMT5 inhibitor administered orally, developed for tumours with an MTAP homozygous deletion.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tng462/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"prmt5-mtap","kind":"target","name":"PRMT5 (MTAP-deleted cancers)","route":"/targets/prmt5-mtap/"}],"company":[{"id":"servier","kind":"company","name":"Servier","route":"/companies/servier/"},{"id":"tango-therapeutics","kind":"company","name":"Tango Therapeutics","route":"/companies/tango-therapeutics/"}],"trial":[{"id":"nct06188702","kind":"trial","name":"S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP","route":"/trials/nct06188702/"},{"id":"nct05732831","kind":"trial","name":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","route":"/trials/nct05732831/"},{"id":"nct06922591","kind":"trial","name":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","route":"/trials/nct06922591/"}]}}